Communiqués Perspective Therapeutics, Inc.

Actions

CATX

US46489V3024

Recherche biotechnologique et médicale

Marché Fermé - NYSE 22:00:00 17/09/2026			Varia. 5j.	Varia. 1 janv.
2,880 ^USD	+6,67%		+3,97%	+4,73%

14/09	Perspective Therapeutics, Inc. et Merck annoncent un accord de collaboration clinique et d'approvisionnement pour évaluer le [212Pb]PSV359 en association avec le Keytruda (pembrolizumab) dans les tumeurs solides positives à la FAP-a	CI
14/09	Perspective Therapeutics conclut une collaboration avec Merck pour un essai clinique en oncologie ; l'action progresse en avant-Bourse	MT

Communiqués

14/09	Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors	AQ
11/09	Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026	AQ
10/08	Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results	AQ
31/07	Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results	AQ
28/07	Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs	AQ
17/07	Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026	AQ
08/07	Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor	AQ
03/06	Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study	AQ
21/05	Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma	AQ
18/05	Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies	AQ
11/05	Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results	AQ
24/04	Perspective Therapeutics to Provide Several Upcoming Corporate Updates	AQ
20/04	Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting	AQ
02/04	Perspective Therapeutics to Participate in Upcoming Investor Conferences	AQ
17/03	Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026	AQ
16/03	Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results	AQ
17/02	Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results	AQ
02/02	Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants	AQ
12/01	Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference	AQ
09/01	Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium	AQ
18/12	Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference	AQ
04/12	Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium	AQ
20/11	Perspective Therapeutics to Participate in Upcoming December Conferences	AQ
10/11	Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results	AQ
31/10/25	Perspective Therapeutics to Participate in Upcoming November Conferences	AQ